# Expanded Access to Tipifarnib

> **NCT04809233** · — · AVAILABLE · sponsor: **Kura Oncology, Inc.**

## Conditions studied

- HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

## Interventions

- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT04809233
- **Lead sponsor:** Kura Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809233, "Expanded Access to Tipifarnib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04809233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*